Agmon-Levin, N., Paz, Z., Israelí, E. y Shoenfeld, Y. (2009). Vacunas y autoinmunidad. Nat Rev Rheumatol, 5, 648-652. https://doi.org/10.1038/nrrheum.2009.196

Anywaine, Z., Whitworth, H., Kaleebu, P., Praygod, G., Shukarev, G., Manno, D., ... y Watson-Jones, D. (2019). Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26. ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. The Journal of infectious diseases, 220(1), 46-56. https://doi.org/10.1093/infdis/jiz070

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... y Zaks, T. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine, 384(5), 403-416. https://doi.org/10.1056/NEJMoa2035389

Calina, D., Docea, AO., Petrakis, D., Egorov, AM., Ishmukhametov, AA., Gabibov, AG., Shtilman, MI., Kostoff, R., Carvalho, F., Vinceti, M., Spandidos, DA. y Tsatsakis, A. (2020). Towards effective COVID 19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med., 46(1), 3-16. https://doi.org/10.3892/ijmm.2020.4596 

Cataño, J. y Aguirre, H. D. (2020). Vacunación del adulto en tiempos de COVID-19. Corporación de Investigaciones Biológicas, 1(2), 1-8.

CDC. (2021). Emerging SARS-CoV-2 Variants. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.htm

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., ... y Balicer, R. D. (2021). BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine, 384(15), 1412-1423. https://doi.org/10.1056/NEJMoa2101765 

Díaz, J. (2018). Análisis de los resultados del Índice Sintético de la Calidad Educativa (ISCE) 2017 de las Secretarías de Educación Certificadas de Colombia. IJERI: International Journal of Educational Research and Innovation, (10), 334-344.

Díaz, J. (2020). Perspectiva del COVID-19 en Colombia para el año 2021. Revista Repertorio de Medicina Y Cirugía, (ed. esp.) 128-133. https://doi.org/10.31260/RepertMedCir.01217372.1136

Díaz, J. (2021). Dinámica y relación del contagio del COVID-19 después de iniciado el plan de vacunación contra el SARS-COV-2 en Colombia. Revista Repertorio De Medicina Y Cirugía, (30), 41-45. https://doi.org/10.31260/RepertMedCir.01217372.1227   

Doshi, P. (2020). ¿Las vacunas covid-19 salvarán vidas? Los ensayos actuales no están diseñados para informarnos. BMJ, 371, m4037. https://doi.org/10.1136/bmj.m4037

Kostoff, R. N., Briggs, M. B., Porter, A. L., Spandidos, D. A. y Tsatsakis, A. (2020b). [Comment] COVID 19 vaccine safety. International journal of molecular medicine, 46(5), 1599-1602. https://doi.org/10.3892/ijmm.2020.4733 

Kostoff, R., Briggs, M. B., Porter, A. L., & Spandidos, D. A. (2020a). COVID-19 vaccine safety. International Journal of Molecular Medicine, 46(5), 1599-1602. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521561/pdf/ijmm-46-05-1599.pdf 

Krause, P. R. y Gruber, M. F. (2020). Emergency use authorization of Covid vaccines—safety and efficacy follow-up considerations. New England Journal of Medicine, 383(19), e107. https://doi.org/10.1056/NEJMp2031373

Mathieu, E., Ritchie, H., Rodés-Guirao, L., Appel, C., Giattino, C., Hasell, J., Macdonald, B., Dattani, S., Beltekian, D., Ortiz-Ospina, E. y Roser, M. (2020). Coronavirus Pandemic (COVID-19). Our World in Data. https://ourworldindata.org/covid-vaccinations https://ourworldindata.org/covid-vaccinations 

Mathioudakis, AG., Ghrew, M., Ustianowski, A., Ahmad, S., Borrow, R., Papavasileiou, LP., Petrakis, D. y Bakerly, ND. (2021). Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel), 11(3), 249. https://doi.org/10.3390/life11030249

Ministerio de Salud y Protección Social de Colombia. (s.f.). Plan de vacunación nacional contra COVID-19. https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... y Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine, 383(27), 2603-2615. https://doi.org/10.1056/NEJMoa2034577

Puthumana, J., Egilman, A. C., Zhang, A. D., Schwartz, J. L. y Ross, J. S. (2021). Speed, evidence, and safety characteristics of vaccine approvals by the US Food and Drug Administration. JAMA Internal Medicine, 181(4), 559-560. https://doi.org/10.1001/jamainternmed.2020.7472

Ramírez, J. A. (2021). Vacunas para COVID-19. Respirar, 13(1), 03-06. https://respirar.alatorax.org/index.php/respirar/article/view/62 

Spinola, S. M., Zimet, G. D., Ott, M. A. y Katz, B. P. (2020). Human challenge studies are unlikely to accelerate coronavirus vaccine licensure due to ethical and practical issues. The Journal of infectious diseases, 222(9), 1572-1574. https://doi.org/10.1093/infdis/jiaa457

World Health Organization. (2023). Organización Mundial de la Salud. Vacunas para COVID-19. 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines 

 World Health Organization. (s.f.). COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines